Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax (NASDAQ: NVAX) announced a non-exclusive license agreement with Pfizer dated January 20, 2026 for use of Novavax's Matrix-M® adjuvant in up to two disease areas. Novavax will receive a $30 million upfront payment and is eligible for up to $500 million in development and sales milestones plus tiered high mid-single digit percent royalties on sales of Pfizer products containing Matrix-M. Pfizer will be solely responsible for development and commercialization of its Matrix-M–containing products, while Novavax will supply Matrix-M for Pfizer's programs.
Novavax (Nasdaq: NVAX) will participate in the 44th Annual J.P. Morgan Healthcare Conference.
The company will present on Wednesday, January 14, 2026 at 4:30 p.m. Pacific Time in San Francisco, CA. A live webcast will be available on the company's Events & Presentations page at ir.novavax.com, and a replay will be available for 30 days following the presentation.
Novavax (Nasdaq: NVAX) will participate in the Jefferies London Healthcare Conference with a fireside chat on Wednesday, November 19, 2025 at 4:30 p.m. GMT in London, United Kingdom.
A webcast of the fireside chat will be available on the company’s Events & Presentations page at ir.novavax.com, and a replay will be accessible for 30 days.
Novavax (NASDAQ: NVAX) reported Q3 2025 total revenue of $70M versus $85M a year earlier and a net loss of $202M. The company earned $225M in Sanofi milestones year‑to‑date, including $50M in Q4 2025 related to marketing authorization transfers. Cash totaled $778M as of September 30, 2025.
Key items: R&D $98M with $46M reimbursed by Sanofi; non‑cash charges $126M (including $97M impairment and $29M debt extinguishment loss); Maryland consolidation yields $60M cash and ~$230M expected savings over 11 years. Full‑year adjusted revenue framework raised to $1,040–$1,060M.
Novavax (Nasdaq: NVAX) completed transfer of U.S. marketing authorization for its COVID-19 vaccine Nuvaxovid to Sanofi after receiving U.S. BLA approval, enabling Sanofi to assume U.S. commercial and regulatory responsibility.
The transfer triggered a second $25 million milestone payment and follows an October 2025 EU transfer, contributing to $225 million of non-dilutive milestone revenue secured year-to-date 2025. Novavax remains eligible for additional milestone payments and royalties under the collaboration and license agreement related to Nuvaxovid, combination products and Matrix-M adjuvant use.
Novavax (Nasdaq: NVAX) will report its third quarter 2025 financial results and operational highlights on November 6, 2025 at 8:30 a.m. ET.
Investors can join the live conference call by registering for an automated callback or dialing the listed numbers. A live webcast and replay will be available at ir.novavax.com/events. The teleconference replay is available from 11:30 a.m. ET on November 6, 2025 until 11:59 p.m. ET on November 13, 2025, and the webcast replay will remain on the investor site until December 5, 2025.
Novavax (Nasdaq: NVAX) executed definitive agreements to transfer one Maryland facility and sell adjacent property, generating $60 million in payments and supporting a planned site consolidation.
The company expects $230 million of future cost savings over 11 years from lower lease expense and facility operating costs. Assignment of the facility lease and sale of related assets are expected to close in January 2026 producing $40 million, while sale of adjacent property is expected to close in Q4 2025 producing $20 million. Novavax headquarters will remain in Gaithersburg, Maryland.
Novavax (Nasdaq: NVAX) completed transfer of the EU marketing authorization for its COVID-19 vaccine Nuvaxovid to Sanofi on Oct 7, 2025, triggering a $25 million milestone payment to Novavax and advancing the companies' collaboration and license agreement.
Novavax remains eligible for additional milestones and tiered royalties including a $25 million U.S. transfer milestone, a $75 million technology-transfer milestone, up to $350 million for certain Sanofi combination-product milestones, up to $200 million for the first four Matrix-M products, and ongoing royalties on sales.
Novavax (Nasdaq: NVAX) has expanded its collaboration with Sanofi through an amended license agreement for Novavax's Matrix-M® adjuvant. The amendment allows Sanofi to use Matrix-M in their pandemic influenza vaccine candidate program through Phase 2 development, supported by BARDA funding.
Under the original agreement terms, Novavax can receive up to $200 million for the first four Sanofi products using Matrix-M, and up to $210 million in milestone payments for each subsequent product, plus ongoing royalties. The companies will negotiate additional terms if Sanofi proceeds to Phase 3 development.
Novavax (NASDAQ:NVAX) has announced that its COVID-19 vaccine Nuvaxovid® has received regulatory approval in Japan, triggering a milestone payment from Takeda. The vaccine is approved for initial immunization in ages 6+ and booster shots for ages 12+, specifically formulated to target the SARS-CoV-2 Omicron LP.8.1 variant.
The approval grants Novavax access to Japan's healthcare market, the world's third-largest. Under the collaboration agreement with Takeda, Novavax will receive undisclosed milestone payments and royalties on net sales, with a portion of the milestone payment applicable to future royalty payments.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
